| Gene symbol | VEGFA | Synonyms | L-VEGF, MVCD1, VEGF, VPF | Type of gene | protein-coding |
| Chromosome | 6 | Map location | 6p21.1 | dbXrefs | |
| Gene perturbation-related omics dataset | PerturbAtlas | PertOrg | ||||
| Description | vascular endothelial growth factor A | ||||
| GTO ID | GTC2469 |
| Trial ID | NCT04567550 |
| Disease | Diabetic Retinopathy |
| Altered gene | VEGFA |
| Therapeutic/Target gene | Therapeutic gene |
| Therapy | Gene transfer |
| Treatment | RGX-314 |
| Phase | Phase2 |
| Recruitment status | Recruiting |
| Title | A Phase 2, Randomized, Dose-escalation, Observation-controlled Study to Evaluate the Efficacy, Safety, and Tolerability of RGX-314 Gene Therapy Delivered Via a Single Suprachoroidal Space (SCS) Injections in Participants With Diabetic Retinopathy (DR) Without Center Involved-Diabetic Macular Edema (CI-DME)(ALTITUDE) |
| Year | 2020 |
| Country | United States |
| Company sponsor | AbbVie |
| Other ID(s) | RGX-314-2202 |
| Vector information | |||||||||
|
|||||||||
| Cohort 1 | |||||||
|
|||||||